Chonluten
Khavinson tripeptide bioregulator (Glu-Asp-Gly) targeting lung tissue — studied for respiratory mucosal restoration and bronchial epithelial cell gene regulation.
🔬 Mechanism of Action
Chonluten (Glu-Asp-Gly, EDG) is a synthetic tripeptide bioregulator targeting pulmonary tissue, with specificity for alveolar type II pneumocytes — the cells responsible for surfactant production that prevents alveolar collapse.
Chonluten modulates gene expression for (1) surfactant proteins SP-A, SP-B, SP-C and SP-D that reduce alveolar surface tension, (2) aquaporin-5 water channels critical for alveolar fluid balance, and (3) secretory IgA — the first-line mucosal immune defense in the lower respiratory tract.
In experimental pneumonia models, Chonluten pre-treatment improved gas exchange efficiency and reduced inflammatory infiltration. It complements Bronchogen (AEDL, bronchial epithelium) by targeting the alveolar/gas-exchange compartment.
Source: PMID: 15677927
📜Background & History
Chonluten (EDG) is the synthetic lung tripeptide targeting alveolar surfactant function.
🎯 Research Use Cases
- ✓Alveolar function support
- ✓Surfactant production
- ✓Respiratory health
💉 Dosing Protocol
| Typical Dose | 10-20 mg/day (oral) or 1-2 mg SC |
| Frequency | 1× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Standard Khavinson protocol. Oral or injectable.
⚡Interactions & Contraindications
Standard Khavinson protocol.
🔗Synergies & Common Stacks
Chonluten (alveolar) + Bronchogen (bronchial) = complementary respiratory tract coverage.